Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Respiratory syncytial virus

Recent news which mentions Respiratory syncytial virus

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
Tags Health care industry Pfizer Inc Merck & Co Inc
From CNBC.com News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
Tags US: News Companies Moderna Inc
From CNBC.com News
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Tags Business News Health & Science Respiratory syncytial virus
From CNBC.com News
RSV vaccine from GSK shows potential to protect adults 50 to 59
Tags Health care industry Biotech and Pharmaceuticals Pfizer Inc
From CNBC.com News
CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
Tags Pfizer Inc Biotech and Pharmaceuticals Health care industry
From CNBC.com News
FDA approves Pfizer maternal RSV vaccine for infants
Tags Social issues AstraZeneca PLC Biotechnology
From CNBC.com News
GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine
Tags Health care industry Vaccinations Walgreens Boots Alliance Inc
From CNBC.com News
GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales
Tags Biotech and Pharmaceuticals Vaccinations Health care industry
From CNBC.com News
CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older
Tags Health care industry Biotech and Pharmaceuticals Pfizer Inc
From CNBC.com News
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
Tags Business News Health & Science Social issues
From CNBC.com News
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults over 60
Tags Health & Science Business News Companies
From CNBC.com News
GSK says RSV vaccine for older adults provides protection over two seasons
Tags Biotech and Pharmaceuticals Pfizer Inc Health care industry
From CNBC.com News
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Tags Biotechnology Respiratory syncytial virus GSK plc
From CNBC.com News
FDA approves Pfizer RSV vaccine for older adults
Tags U/S/ Economy Health care industry Policy
From CNBC.com News
Here’s what Pfizer and Moderna say is next for their Covid vaccines
Tags Health care industry Coronavirus Flu
From CNBC.com News
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Tags Science Immunizations Business
From CNBC.com News
Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say
Tags Business News Health & Science Respiratory syncytial virus
From CNBC.com News
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
Tags Pfizer Inc Breaking news Science
From CNBC.com News
FDA says Guillain-Barre syndrome is possible risk of Pfizer's RSV vaccine for older adults
Tags Policy Vaccinations U/S/ Economy
From CNBC.com News
Moderna, Pfizer's new race: The RSV vaccine FDA approval process
Tags Immunizations Vaccinations Technology
From CNBC.com News
A nutritionist shares the best snacks to bring on a plane to boost your immune system
Tickers LIFE
Tags Coronavirus Hospitality and leisure industry Infectious diseases
From CNBC.com News
Why flu season is so bad this year
Tickers LIFE
Tags U/S/ Economy Health care industry Policy
From CNBC.com News
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data shows
Tags Pandemics US Top News and Analysis Politics
From CNBC.com News
Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV
Tickers AZN AZNCF SNY
Tags Biotech Health Care Benzinga
From Benzinga
Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults
Tickers PFE
Tags Market News FDA General
From Benzinga
Johnson & Johnson Posts Additional RSV Vaccine Data
Tickers JNJ
Tags Market News Phase 2 Trial REspiratory syncytial virus
From Benzinga
J&J's RSV Vaccine Candidate Shows 80% Efficacy In Older Adults
Tickers JNJ
Tags General REspiratory syncytial virus Market News
From Benzinga
Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients
Tickers PFE
Tags Health Care Phase 3 Trial Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.